Company: RGNT
Filing Date: 2025-10-24
Form Type: F-1/A
Source: 0001213900-25-101900
Chunk: 111

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-10-24
Form: F-1/A
Chunk 111
---
 June 30, 2025 and 2024.

There was no net cash used
in investing activities during the years ended December 31, 2024 and 2023.

Net cash provided by (used in) financing activities

Net cash provided by financing
activities increased by $0.5 million, to approximately $0.3 million for the six months ended June 30, 2025 compared to net cash used
in finance activities of approximately $0.2 million for the six months ended June 30, 2024. This increase was due to proceeds from short-term
loan in 2025 compared to a repayment net of short-term loans in 2024.

Net cash provided by financing
activities increased by approximately $0.2 million, to approximately $0.5 million for the year ended December 31, 2024 compared to $0.3
million for the year ended December 31, 2023. This increase was due to higher proceeds from short-term loan in 2024.

Funding Requirements

We have incurred losses
from operations since the inception, resulting in an accumulated deficit on June 30, 2025 and December 31, 2024 of approximately $45.3 million
and $42.1 million, respectively. We anticipate that we will continue to incur net losses for the foreseeable future. We believe that
our existing cash and cash equivalents, without giving effect to the proceeds from this offering, will be sufficient to fund our projected
cash needs until October 2025. To meet future capital needs, we would need to raise additional capital through equity or debt financing
or other strategic transactions. However, any such financing may not be on favorable terms or even available to us. Our failure to obtain
sufficient funds on commercially acceptable terms when needed would have a material adverse effect on our business, results of operations
and financial condition. Our forecast of the period of time through which our financial resources will be adequate to support our operations
is a forward-looking statement that involves risks and uncertainties, and the actual amount of our expenses could vary materially and
adversely as a result of a number of factors. We have based our estimates on assumptions that may prove to be wrong, and our expenses
could prove to be significantly higher than we currently anticipate.

Our future capital requirements
will depend on many factors, including, but not limited to:

| ● | the progress and costs                      
 of our research and development activities; |

| ● | the costs